When was Ellume founded?

Ellume was founded in 2010 and raised its 1st funding round 9 years after it was founded.

Where is Ellume located?

Ellume is headquartered in Brisbane, Australia.

Is Ellume a funded company?

Ellume is a funded company, having raised a total of $5M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 17, 2019.

When was the latest funding round of Ellume?

Ellume's latest funding was a $***** Grant (prize money) round on Feb 01, 2021, with participation from 2 investors.

Where does Ellume rank among its competitors?

Ellume ranks 9th amongst 27 active competitors, of which 8 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Tethis, which secured $15.3M in Jan, 2025.

Who are the top competitors of Ellume?

Ellume's top competitors include InDevR, Tethis and Entopsis. Among them, Tethis secured the most recent funding round in January, 2025.

Ellume - 2026 Company Profile, Team, Funding & Competitors

Company Details

Ellume has is a developer of a diagnostic device that uses quantum dot fluorescent nanoparticles as biological detectors. It provides real-time patient testing with features such as encrypted patient data and images, connectivity to access user information, and claims to provides results in approximately seven minutes. The company has developed tests for Influenza A+B, Respiratory Syncytial Virus, Group A Streptococcus, and aims to create tests for more respiratory viruses and bacterial infections.

Website: ellumehealth.com
Social
Phone Number: +61 **********

Key Metrics

Founded Year

2010

Location

Brisbane, Australia

Stage

Series A

Total Funding

$5M in 2 rounds

Latest Funding Round

Grant (prize money), Feb 01, 2021, $*****

Investors

Defense.gov & 1 more

Ranked

9^th among 27 active competitors

Similar Companies

InDevR & 46 more

View Ellume's full profile

Ellume has raised a total funding of $5M over 2 rounds. Its first funding round was on Jun 17, 2019. Its latest funding round was a Grant (prize money) round on Feb 01, 2021 for $*****. 2 investors participated in its latest round. Ellume has 2 institutional investors.

Here is the list of recent funding rounds of Ellume:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 01, 2021	1160626	Grant (prize money)	9367648	3970691	1966683	6224348
Jun 17, 2019	3969993	Series A	3452132	2872100	9789981	7143088

Access funding benchmarks and valuations. Sign up today!

View details of Ellume's funding rounds and investors

The founders of Ellume is Sean Parsons.

Here are the details of Ellume's key team members:

Sean Parsons: Founder & MD of Ellume.

View details of Ellume's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ellume include InDevR, Tethis and Entopsis. Here is the list of Top 10 competitors of Ellume, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	InDevR 2003, Boulder (United States), Acquired	Manufacturer of biotherapeutics, vaccines and diagnostic products	$16M	Adjuvant Capital, BioMerieux & 2 others	57/100
2nd	Tethis 2004, Milan (Italy), Series A	Provider of automated solutions for in liquid biopsy	$15.3M	sanpaolope.com, Indaco Venture Partners & 5 others	55/100
3rd	Entopsis 2011, Miami (United States), Series A	Developer of diagnostic device for regular health monitoring	$2.09M	Krillion Ventures, Breakout Labs & 1 others	42/100
4th	GNA Biosolutions 2010, Planegg (Germany), Series C	Develops instruments, OEM modules and assays for molecular pathogen detection	$20.2M	Bayern Kapital, OCCIDENT & 11 others	41/100
5th	Diagnostic Hybrids 1983, Athens (United States), Acquired	Developer of molecular diagnostics kits for infectious diseases	$10M	Summit Partners, Kenson Ventures	41/100
6th	NanoVation-GS 2014, Haifa (Israel), Series A	Provider of sensor-based respiratory parameters monitoring device	$5.9M	EIC Fund, Europa	40/100
7th	IQuum 1999, United States, Acquired	Lab-in-a-tube technology for rapid diagnostics	$1M	IBS Capital, HHS	38/100
8th	BioMedomics 2006, Durham (United States), Seed	Point of care diagnostic systems for blood-based disorders	$1.5M	NLVC, NIH & 1 others	36/100
9th	Ellume 2010, Brisbane (Australia), Series A	Developer of a diagnostic device that uses quantum dot nanoparticles to provide real-time patient testing	$5M	Defense.gov, HHS	36/100
10th	Nanotis 2016, Tokyo (Japan), Series A	Microfluidic chip based diagnostic test for influenza	$1.13M	Shizuoka Financial Group, Hamamatsu Photonics ... & 1 others	34/100